Influence of tumour necrosis factor alpha on the outcome of ischaemic postconditioning in the presence of obesity and diabetes

Experimental Diabetes Research

Volumn 2012, Issue , 2012, Pages

  Lacerda, Lydia ^a   Opie, Lionel H ^a   Lecour, Sandrine ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; INSULIN; LEPTIN; STREPTOZOCIN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CARBOHYDRATE DIET; CONTROLLED STUDY; DIABETES MELLITUS; GLUCOSE BLOOD LEVEL; HEART MUSCLE REPERFUSION; HEART PROTECTION; HEART WEIGHT; ISCHEMIC POSTCONDITIONING; MOUSE; NONHUMAN; OBESITY; PRIORITY JOURNAL; ANIMAL; BLOOD; CARDIOMEGALY; DISEASE PREDISPOSITION; GENETICS; HEART; HEART MUSCLE; HEART MUSCLE ISCHEMIA; HYPERGLYCEMIA; HYPERINSULINISM; IN VITRO STUDY; INSULIN DEPENDENT DIABETES MELLITUS; METABOLISM; MOUSE MUTANT; ORGAN SIZE; PATHOLOGY; PATHOPHYSIOLOGY; REPERFUSION INJURY; SEVERITY OF ILLNESS INDEX;

ANIMALS; CARDIOMEGALY; DIABETES MELLITUS, TYPE 1; DIETARY CARBOHYDRATES; DISEASE SUSCEPTIBILITY; HEART; HYPERGLYCEMIA; HYPERINSULINISM; ISCHEMIC POSTCONDITIONING; LEPTIN; MICE; MICE, KNOCKOUT; MYOCARDIAL ISCHEMIA; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; OBESITY; ORGAN SIZE; SEVERITY OF ILLNESS INDEX; STREPTOZOCIN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84869003208     PISSN: 16875214     EISSN: 16875303     Source Type: Journal    
DOI: 10.1155/2012/502654     Document Type: Article

References (49)

1. Flegal K. M., Carroll M. D., Ogden C. L., Johnson C. L., Prevalence and trends in obesity among US adults, 1999-2000. JAMA 2002 288 14 1723 1727 2-s2.0-0037048669
2. Lavie C. J., Milani R. V., Obesity and cardiovascular disease: the Hippocrates paradox? Journal of the American College of Cardiology 2003 42 4 677 679 2-s2.0-0042731928 10.1016/S0735-1097(03)00784-8 (Pubitemid 37000184)
3. Manson J. E., Bassuk S. S., Obesity in the United States: a fresh look at its high toll. JAMA 2003 289 2 229 230 2-s2.0-0037425547 10.1001/jama.289.2.229 (Pubitemid 36068713)
4. Orchard T. J., Costacou T., Kretowski A., Nesto R. W., Type 1 diabetes and coronary artery disease. Diabetes Care 2006 29 11 2528 2538 2-s2.0-33845490687 10.2337/dc06-1161 (Pubitemid 44912266)
5. Aasum E., Khalid A. M., Gudbrandsen O. A., How O. J., Berge R. K., Larsen T. S., Fenofibrate modulates cardiac and hepatic metabolism and increases ischemic tolerance in diet-induced obese mice. Journal of Molecular and Cellular Cardiology 2008 44 1 201 209 2-s2.0-37549067407 10.1016/j.yjmcc.2007.08.020
6. Aronson D., Weinrauch L. A., D'Elia J. A., Tofler G. H., Burger A. J., Circadian patterns of heart rate variability, fibrinolytic activity, and hemostatic factors in type I diabetes mellitus with cardiac autonomic neuropathy. American Journal of Cardiology 1999 84 4 449 453 2-s2.0-0033566837 10.1016/S0002-9149(99)00331-8 (Pubitemid 29398667)
7. Sack M. N., Murphy E., The role of comorbidities in cardioprotection. Journal of Cardiovascular Pharmacology and Therapeutics 2011 16 3-4 267 272 2-s2.0-80051502724 10.1177/1074248411408313
8. Bouhidel O., Pons S., Souktani R., Zini R., Berdeaux A., Ghaleh B., Myocardial ischemic postconditioning against ischemia-reperfusion is impaired in ob/ob mice. American Journal of Physiology 2008 295 4 H1580 H1586 2-s2.0-57049120648 10.1152/ajpheart.00379.2008
9. Hotamisligil G. S., Arner P., Caro J. F., Atkinson R. L., Spiegelman B. M., Increased adipose tissue expression of tumor necrosis factor- α in human obesity and insulin resistance. The Journal of Clinical Investigation 1995 95 5 2409 2415 2-s2.0-0028931724
10. Margetic S., Gazzola C., Pegg G. G., Hill R. A., Leptin: a review of its peripheral actions and interactions. International Journal of Obesity 2002 26 11 1407 1433 2-s2.0-0036866913 10.1038/sj.ijo.0802142 (Pubitemid 36007818)
11. Smith C. C. T., Mocanu M. M., Davidson S. M., Wynne A. M., Simpkin J. C., Yellon D. M., Leptin, the obesity-associated hormone, exhibits direct cardioprotective effects. British Journal of Pharmacology 2006 149 1 5 13 2-s2.0-33748030752 10.1038/sj.bjp.0706834 (Pubitemid 44299063)
12. Smith C. C. T., Dixon R. A., Wynne A. M., Theodorou L., Ong S. G., Subrayan S., Davidson S. M., Hausenloy D. J., Yellon D. M., Leptin-induced cardioprotection involves JAK/STAT signaling that may be linked to the mitochondrial permeability transition pore. American Journal of Physiology 2010 299 4 H1265 H1270 2-s2.0-77958027773 10.1152/ajpheart.00092.2010
13. Skyschally A., Gres P., Hoffmann S., Haude M., Erbel R., Schulz R., Heusch G., Bidirectional role of tumor necrosis factor- α in coronary microembolization: progressive contractile dysfunction versus delayed protection against infarction. Circulation Research 2007 100 1 140 146 2-s2.0-33846092559 10.1161/01.RES.0000255031.15793.86 (Pubitemid 46066782)
14. Sack M. N., Tumor necrosis factor- α in cardiovascular biology and the potential role for anti-tumor necrosis factor- α therapy in heart disease. Pharmacology and Therapeutics 2002 94 1-2 123 135 2-s2.0-0036016257 10.1016/S0163-7258(02)00176-6 (Pubitemid 34615962)
15. Schulz R., TNF α in myocardial ischemia/reperfusion: damage vs. protection. Journal of Molecular and Cellular Cardiology 2008 45 6 712 714 2-s2.0-55649115951 10.1016/j.yjmcc.2008.09.119
16. Schulz R., Heusch G., Editorial: tumor necrosis factor- α and its receptors 1 and 2: yin and yang in myocardial infarction? Circulation 2009 119 10 1355 1357 2-s2.0-64549121172 10.1161/CIRCULATIONAHA.108.846105
17. Lacerda L., Somers S., Opie L. H., Lecour S., Ischaemic postconditioning protects against reperfusion injury via the SAFE pathway. Cardiovascular Research 2009 84 2 201 208 2-s2.0-71549129836 10.1093/cvr/cvp274
18. Wu K. K., Huan Y., Streptozotocin-induced diabetic models in mice and rats. Current Protocols in Pharmacology 2008 40 5.47.1 5.47.14 2-s2.0-57349184120 10.1002/0471141755.ph0547s40
19. Smith R. M., Suleman N., McCarthy J., Sack M. N., Classic ischemic but not pharmacologic preconditioning is abrogated following genetic ablation of the TNF α gene. Cardiovascular Research 2002 55 3 553 560 2-s2.0-0036023629 10.1016/S0008-6363(02)00283-3 (Pubitemid 34874950)
20. Nakamura T., Terajima T., Ogata T., Ueno K., Hashimoto N., Ono K., Yano S., Establishment and pathophysiological characterization of type 2 diabetic mouse model produced by streptozotocin and nicotinamide. Biological and Pharmaceutical Bulletin 2006 29 6 1167 1174 2-s2.0-33744918517 10.1248/bpb.29.1167 (Pubitemid 43845477)
21. Ovize M., Baxter G. F., Di Lisa F., Ferdinandy P., Garcia-Dorado D., Hausenloy D. J., Heusch G., Vinten-Johansen J., Yellon D. M., Schulz R., Postconditioning and protection from reperfusion injury: where do we stand: position Paper from the Working Group of Cellular Biology of the Heart of the European Society of Cardiology. Cardiovascular Research 2010 87 3 406 423 2-s2.0-77954789419 10.1093/cvr/cvq129
22. Heusch G., Obesitya risk factor or a RISK factor for myocardial infarction? British Journal of Pharmacology 2006 149 1 1 3 2-s2.0-33748078113 10.1038/sj.bjp.0706833 (Pubitemid 44299062)
23. Hausenloy D. J., Baxter G., Bell R., Botker H. E., Davidson S. M., Downey J., Heusch G., Kitakaze M., Lecour S., Mentzer R., Mocanu M. M., Ovize M., Schulz R., Shannon R., Walker M., Walkinshaw G., Yellon D. M., Translating novel strategies for cardioprotection: the Hatter Workshop Recommendations. Basic Research in Cardiology 2010 105 6 677 686 2-s2.0-78649320661 10.1007/s00395-010-0121-4
24. Schwartz Longacre L., Kloner R. A., Arai A. E., Baines C. P., Bolli R., Braunwald E., Downey J., Gibbons R. J., Gottlieb R. A., Heusch G., Jennings R. B., Lefer D. J., Mentzer R. M., Murphy E., Ovize M., Ping P., Przyklenk K., Sack M. N., Vander Heide R. S., Vinten-Johansen J., Yellon D. M., New horizons in cardioprotection: recommendations from the 2010 national heart, lung, and blood institute workshop. Circulation 2011 124 10 1172 1179 2-s2.0-84857017353 10.1161/CIRCULATIONAHA.111.032698
25. Fuglesteg B. N., Suleman N., Tiron C., Kanhema T., Lacerda L., Andreasen T. V., Sack M. N., Jonassen A. K., Mjos O. D., Opie L. H., Lecour S., Signal transducer and activator of transcription 3 is involved in the cardioprotective signalling pathway activated by insulin therapy at reperfusion. Basic Research in Cardiology 2008 103 5 444 453 2-s2.0-50249152907 10.1007/s00395-008-0728-x
26. Przyklenk K., Maynard M., Greiner D. L., Whittaker P., Cardioprotection with postconditioning: loss of efficacy in murine models of type-2 and type-1 diabetes. Antioxidants and Redox Signaling 2011 14 5 781 790 2-s2.0-79551672046 10.1089/ars.2010.3343
27. Skyschally A., van Caster P., Iliodromitis E. K., Schulz R., Kremastinos D. T., Heusch G., Ischemic postconditioning: experimental models and protocol algorithms. Basic Research in Cardiology 2009 104 5 469 483 2-s2.0-70349665133 10.1007/s00395-009-0040-4
28. Somers S. J., Lacerda L., Opie L., Lecour S., Age, genetic characteristics and number of cycles are critical factors to consider for successful protection of the murine heart with postconditioning. Physiological Research 2011 60 6 971 974 2-s2.0-84856425470
29. Kleinbongard P., Heusch G., Schulz R., TNF α in atherosclerosis, myocardial ischemia/reperfusion and heart failure. Pharmacology and Therapeutics 2010 127 3 295 314 2-s2.0-77954242107 10.1016/j.pharmthera.2010.05.002
30. Lecour S., Suleman N., Deuchar G. A., Somers S., Lacerda L., Huisamen B., Opie L. H., Pharmacological preconditioning with tumor necrosis factor- α activates signal transducer and activator of transcription-3 at reperfusion without involving classic prosurvival kinases (Akt and extracellular signal-regulated kinase). Circulation 2005 112 25 3911 3918 2-s2.0-33644876126 10.1161/CIRCULATIONAHA.105.581058 (Pubitemid 43739489)
31. Lecour S., Smith R. M., Woodward B., Opie L. H., Rochette L., Sack M. N., Identification of a novel role for sphingolipid signaling in TNF α and ischemic preconditioning mediated cardioprotection. Journal of Molecular and Cellular Cardiology 2002 34 5 509 518 2-s2.0-0036586721 10.1006/jmcc.2002.1533
32. Lacerda L., McCarthy J., Mungly S. F. K., Lynn E. G., Sack M. N., Opie L. H., Lecour S., TNF α protects cardiac mitochondria independently of its cell surface receptors. Basic Research in Cardiology 2010 105 6 751 762 2-s2.0-78649318067 10.1007/s00395-010-0113-4
33. Lecour S., Activation of the protective Survivor Activating Factor Enhancement (SAFE) pathway against reperfusion injury: does it go beyond the RISK pathway? Journal of Molecular and Cellular Cardiology 2009 47 1 32 40 2-s2.0-67349229765 10.1016/j.yjmcc.2009.03.019
34. Boengler K., Hilfiker-Kleiner D., Heusch G., Schulz R., Inhibition of permeability transition pore opening by mitochondrial STAT3 and its role in myocardial ischemia/reperfusion. Basic Research in Cardiology 2010 105 6 771 785 2-s2.0-78649324875 10.1007/s00395-010-0124-1
35. Yokoyama T., Nakano M., Bednarczyk J. L., McIntyre B. W., Entman M., Mann D. L., Tumor necrosis factor- α provokes a hypertrophic growth response in adult cardiac myocytes. Circulation 1997 95 5 1247 1252 2-s2.0-0031017263 (Pubitemid 27097837)
36. Hotamisligil G. S., Shargill N. S., Spiegelman B. M., Adipose expression of tumor necrosis factor- α: direct role in obesity-linked insulin resistance. Science 1993 259 5091 87 91 2-s2.0-0027459878 (Pubitemid 23036092)
37. Montoro-García S., Shantsila E., Marín F., Blann A., Lip G. Y. H., Circulating microparticles: new insights into the biochemical basis of microparticle release and activity. Basic Research in Cardiology 2011 1 13 2-s2.0-79958791248 10.1007/s00395-011-0198-4
38. Schreyer S. A., Chua S. C., Leboeuf R. C., Obesity and diabetes in TNF- α receptor-deficient mice. The Journal of Clinical Investigation 1998 102 2 402 411 2-s2.0-0032528177 (Pubitemid 28335200)
39. Hotamisligil G. S., Murray D. L., Choy L. N., Spiegelman B. M., Tumor necrosis factor α inhibits signaling from the insulin receptor. Proceedings of the National Academy of Sciences of the United States of America 1994 91 11 4854 4858 2-s2.0-0028362194 10.1073/pnas.91.11.4854 (Pubitemid 24177748)
40. Hotamisligil G. S., Spiegelman B. M., Tumor necrosis factor α: a key component of the obesity-diabetes link. Diabetes 1994 43 11 1271 1278 2-s2.0-0028587742
41. Rothwell N. J., Cytokines and thermogenesis. International Journal of Obesity 1993 17 supplement 3 S98 S115
42. Fargeas M. J., Fioramonti J., Bueno L., Central action of interleukin 1 β on intestinal motility in rats: mediation by two mechanisms. Gastroenterology 1993 104 2 377 383 2-s2.0-0027390244 (Pubitemid 23033408)
43. Arbos J., Lopez-Soriano F. J., Carbo N., Argiles J. M., Effects of tumour necrosis factor- α (cachectin) on glucose metabolism in the rat. Intestinal absorption and isolated enterocyte metabolism. Molecular and Cellular Biochemistry 1992 112 1 53 59 2-s2.0-0026627992
44. Hotamisligil G. S., Budavari A., Murray D., Spiegelman B. M., Reduced tyrosine kinase activity of the insulin receptor in obesity- diabetes. Central role of tumor necrosis factor- α The Journal of Clinical Investigation 1994 94 4 1543 1549 2-s2.0-0028031569
45. Hotamisligil G. S., Inflammatory pathways and insulin action. International Journal of Obesity 2003 27 supplement 3 S53 S55 2-s2.0-0346880504 10.1038/sj.ijo.0802502 (Pubitemid 38019190)
46. Kennedy L. M. A., Dickstein K., Anker S. D., Kristianson K., Willenheimer R., The prognostic importance of body mass index after complicated myocardial infarction. Journal of the American College of Cardiology 2005 45 1 156 158 2-s2.0-11144236980 10.1016/j.jacc.2004.10.001 (Pubitemid 40052042)
47. Nikolsky E., Stone G. W., Grines C. L., Cox D. A., Garcia E., Tcheng J. E., Griffin J. J., Guagliumi G., Stuckey T., Turco M., Negoita M., Lansky A. J., Mehran R., Impact of body mass index on outcomes after primary angioplasty in acute myocardial infarction. American Heart Journal 2006 151 1 168 175 2-s2.0-29144459124 10.1016/j.ahj.2005.03.024 (Pubitemid 41815349)
48. Dixon R. A., Davidson S. M., Wynne A. M., Yellon D. M., Smith C. C. T., The cardioprotective actions of leptin are lost in the zucker obese (fa/fa) rat. Journal of Cardiovascular Pharmacology 2009 53 4 311 317 2-s2.0-77958027773 10.1097/FJC.0b013e31819d6152
49. Dixon R. A., Davidson S. M., Wynne A. M., Yellon D. M., Smith C. C. T., The cardioprotective actions of leptin are lost in the zucker obese (fa/fa) rat. Journal of Cardiovascular Pharmacology 2009 53 4 311 317 2-s2.0-67650364184 10.1097/FJC.0b013e31819d6152